title: Short term effect of atorvastatin and vitamin E on serum levels of C3, a sensitive marker of the risk of myocardial infarction in men.
abstract: C3 complement is produced in response to macrophage activation and is a reliable marker of the risk of myocardial infarction in men. This study was designed to ascertain whether the treatment with atorvastatin, a powerful cholesterol lowering drug, and/or vitamin E, a natural antioxidant, may induce a short term decrease in serum C3 in subjects with persistently elevated levels. From an initial random sample of 1100 men aged 55-64 years, 140 subjects with 3 consecutive C3 measurements in the high tertile (>1.19 g/l) were selected. Those with total cholesterol <5.56 mmol/l were double blindly randomized in groups 1 (placebo, N = 28, G1) and 2 (vitamin E 600 IU/day, N= 30, G2). The subjects with total cholesterol values >5.56 mmol/l were randomized in groups 3 (placebo, N= 30, G3), 4 (atorvastatin 10 mg/day, N = 27, G4) and 5 (atorvastatin 10 mg/day + vitamin E 600 IU/day, N = 25, G5). After 3 months C3 levels were substantially unchanged in the first 4 groups, while in G5 a very significant decrement occurred: -0.070 g/l (5.2%); 95% CI 0.043-0.098; p <0.0001. "Normal" levels of C3 (< 1.19 g/l) were reached by 28% of G5 subjects. In G2 and G5 vitamin E levels increased by 60 and 36%, while in G4 they decreased by 23% (p < 0.0001), paralleling cholesterol and triglyceride fall. In all groups a progressive decrease in HDL cholesterol occurred (-17%, p < 0.0001). In conclusion, treatment with atorvastatin plus vitamin E for three months can lower persistently elevated C3 levels.
authors.affiliation: Department of Internal Medicine, Cardioangiology, University of Bologna, Italy. amuscari@med.unibo.it
authors.forename: A
authors.initials: A
authors.lastname: Muscari
authors.forename: L
authors.initials: L
authors.lastname: Bastagi
authors.forename: G
authors.initials: G
authors.lastname: Poggiopollini
authors.forename: V
authors.initials: V
authors.lastname: Tomassetti
authors.forename: G
authors.initials: G
authors.lastname: Massarelli
authors.forename: P
authors.initials: P
authors.lastname: Boni
authors.forename: P
authors.initials: P
authors.lastname: Puddu
mesh_terms: D000924:Anticholesteremic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000975:Antioxidants / Q000008:administration & dosage* / Q000009:adverse effects; D000069059:Atorvastatin; D015415:Biomarkers; D008076:Cholesterol, HDL / Q000097:blood; D015932:Complement C3c / Q000378:metabolism*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D006538:Heptanoic Acids / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000378:metabolism; D011758:Pyrroles / Q000008:administration & dosage* / Q000009:adverse effects; D012307:Risk Factors; D014810:Vitamin E / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000924:Anticholesteremic Agents; D000975:Antioxidants; D015415:Biomarkers; D008076:Cholesterol, HDL; D006538:Heptanoic Acids; D011758:Pyrroles; D014810:Vitamin E; D015932:Complement C3c; D000069059:Atorvastatin